Difference between revisions of "Kaposi sarcoma - null regimens"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "While not clinically relevant, these references provide further insight into the historical development of the treatment landscape" to "These references provide further insight into the historical development of the treatment landscape") |
||
Line 1: | Line 1: | ||
− | The purpose of this page is to provide references to "null therapy" such as placebo and observation. | + | The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the [[Kaposi sarcoma|main KS page]] for current regimens. |
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} |
Revision as of 12:14, 14 October 2023
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main KS page for current regimens.
All lines of therapy
Placebo
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Noy et al. 2005 (AMC 013) | 1998-2001 | Phase 3 (C) | IM-862 | Seems to have superior TTP |
No active antineoplastic treatment.
References
- AMC 013: Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. link to original article PubMed